|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM104106344 |
| 003 |
DE-627 |
| 005 |
20231222131816.0 |
| 007 |
tu |
| 008 |
231222s1999 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0347.xml
|
| 035 |
|
|
|a (DE-627)NLM104106344
|
| 035 |
|
|
|a (NLM)10479534
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Breen, E C
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6
|
| 264 |
|
1 |
|c 1999
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.10.1999
|
| 500 |
|
|
|a Date Revised 19.11.2015
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 1999 Academic Press.
|
| 520 |
|
|
|a B cell hyperactivation accompanies HIV infection and is believed to contribute to the increased incidence of B cell lymphoma in persons with AIDS. To examine B cell activation which precedes the development of AIDS-associated lymphoma, we measured levels of two B cell stimulatory molecules, soluble CD23 (sCD23) and interleukin 6 (IL6), in the serum of HIV-infected individuals prior to the diagnosis of lymphoma. Serum sCD23 was elevated in those subjects who developed lymphoma, compared to AIDS, HIV+, and HIV- controls (P = 0.001). Serum IL6 was significantly elevated in subjects who developed Burkitt's/small noncleaved cell lymphoma (BL/SNC, P = 0.01), but not in those subjects who developed large cell, immunoblastic, or central nervous system lymphomas, compared to CD4-matched AIDS controls who did not have lymphoma. These results suggest that lymphomagenesis of the BL/SNC subtype of AIDS lymphoma reflects B cell hyperactivation of a different nature from that which precedes other subtypes of AIDS-associated B cell lymphoma
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-6
|2 NLM
|
| 650 |
|
7 |
|a Receptors, IgE
|2 NLM
|
| 700 |
1 |
|
|a van der Meijden, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cumberland, W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kishimoto, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Detels, R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Martínez-Maza, O
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 92(1999), 3 vom: 15. Sept., Seite 293-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:92
|g year:1999
|g number:3
|g day:15
|g month:09
|g pages:293-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 92
|j 1999
|e 3
|b 15
|c 09
|h 293-9
|